Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Alto Neuroscience, Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness of its drug ALTO-100 for treating major depressive disorder (MDD) [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the September 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Alto [4]. - Investors who purchased Alto stock during the class period from February 2, 2024, to October 22, 2024, are encouraged to discuss their legal rights [1][4]. - The complaint alleges that Alto and its executives made false statements regarding ALTO-100's effectiveness, overstating its clinical and commercial prospects [6]. Group 2: Stock Performance and Market Reaction - Following the announcement on October 22, 2024, that ALTO-100 did not meet its primary endpoint in a Phase 2b trial, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 per share [7]. - Analysts reacted swiftly, with Jeffries reducing its price target for Alto from $33 to $17, citing concerns about the company's biomarker approach to CNS disorders [8]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Alto Neuroscience, Inc. due to allegations of misleading statements regarding the effectiveness of its drug ALTO-100 for treating major depressive disorder (MDD) [2][4]. Group 1: Legal Investigation - The firm is reminding investors of the September 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Alto [2]. - The complaint alleges that Alto and its executives violated federal securities laws by making false statements about ALTO-100's effectiveness and overstating the company's business prospects [4][5]. Group 2: Financial Impact - Following the announcement that ALTO-100 did not meet its primary endpoint in a Phase 2b trial, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 on October 23, 2024 [5]. - Analysts reacted by cutting their price target for Alto from $33 to $17, raising concerns about the company's overall approach to CNS disorders and psychiatry [6]. Group 3: Class Action Details - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members [7]. - Faruqi & Faruqi encourages anyone with information regarding Alto's conduct to contact the firm, including whistleblowers and former employees [7].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, leading to overstated clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. during the IPO and the subsequent class period about the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased Alto securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit alleges that during the class period, Alto made materially false and misleading statements regarding its business and the effectiveness of its product ALTO-100 [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Allegations Against Alto Neuroscience - The lawsuit claims that Alto misrepresented the effectiveness of ALTO-100 in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [5]. - As a result of these misrepresentations, Alto's business and financial prospects were also overstated, leading to investor damages when the truth was revealed [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's product pipeline and financial prospects [1][4]. Group 1: Class Action Details - The class action lawsuit is on behalf of all persons and entities that purchased Alto common stock during the class period from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although it is not required to partake in any recovery [1][5]. Group 2: Allegations - The complaint alleges that during the class period, the defendants made materially false and misleading statements regarding the effectiveness of the product ALTO-100 in treating major depressive disorder [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to an inflated perception of Alto's business and financial prospects [4]. Group 3: Next Steps for Shareholders - Shareholders must register by September 19, 2025, to participate in the class action and will be enrolled in a portfolio monitoring software for updates [5]. - There is no cost or obligation for shareholders to participate in the case [5]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered from deceit and fraud [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [6].

Core Points - A class action lawsuit has been filed against Alto Neuroscience, Inc. for violations of federal securities laws [1][2] - The lawsuit claims that Alto made false and misleading statements regarding the effectiveness of its treatment ALTO-100 for major depressive disorder [2] - The class period for the lawsuit is from February 2, 2024, the date of Alto's IPO, to October 22, 2024 [2] Company Details - Shareholders who purchased shares during the class period are encouraged to contact DJS Law Group for potential lead plaintiff appointments [1][3] - The deadline for shareholders to register for participation in the lawsuit is September 19, 2025 [2] - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4]

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its product pipeline and business prospects [1][2]. Group 1: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [1]. - Shareholders are encouraged to register for the class action by September 19, 2025, to potentially be appointed as lead plaintiff [3]. Group 2: Allegations Against Alto Neuroscience - The complaint alleges that the product pipeline, specifically ALTO-100, was less effective in treating major depressive disorder than previously claimed, leading to overstated clinical and commercial prospects [2]. - As a result of these misleading statements, Alto's overall business and financial outlook were also overstated [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [4].

Core Viewpoint - Alto Neuroscience, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the effectiveness of its drug ALTO-100 during its IPO and subsequent clinical trials [3][4][5]. Company Overview - Alto Neuroscience operates as a clinical-stage biopharmaceutical company [3]. - The company conducted its IPO on February 2, 2024, issuing over 8 million shares at $16.00 per share, raising over $119 million [3]. Product Pipeline - The product pipeline includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of the IPO [3]. Allegations of Misleading Information - The lawsuit claims that the company made false or misleading statements about ALTO-100's effectiveness in treating MDD, overstating its clinical, regulatory, and commercial prospects [4]. - It is alleged that these misrepresentations led to an overestimation of Alto Neuroscience's overall business and financial prospects [4]. Impact of Clinical Trial Results - On October 22, 2024, the company announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, resulting in a nearly 70% drop in stock price [5]. - Following this announcement, Alto Neuroscience's stock continued to trade below the IPO price of $16.00 per share [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. during the IPO and the subsequent class period about the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased Alto securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit alleges that during the class period, Alto made materially false and misleading statements regarding its business and the effectiveness of its product ALTO-100 for treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4].

Core Viewpoint - A class action has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Company Overview - Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. Group 2: Allegations and Misconduct - The complaint alleges that the Offering Documents for the IPO were negligently prepared and that the company failed to disclose that ALTO-100 was less effective in treating MDD than represented, leading to overstated clinical, regulatory, and commercial prospects [2]. - The company's business and financial prospects were also claimed to be overstated as a result of these misrepresentations [2]. Group 3: Impact of Trial Results - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, resulting in a significant stock price drop of $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Group 4: Class Action Participation - Shareholders interested in participating in the class action against Alto have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4].